Recent Updates
Recently added Catalysts

ProKidney Corp.

PROKFDA catalysts, PDUFA dates & pipeline intelligence
$1.11
▼ -0.04 · -3.48%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full PROK financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.8752W HIGH $2.88
Volume
733.34 K
Value Traded
806.53 K
Short % Float
21.91%
Days to Cover
20.8
-0.89%Week
-33.53%1 Month
-25%3 Month
-36.57%6 Month
-82.59%5 Year
-82.59%All Time

Cash Data

Unlock PROK cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
335.58 M
EPS (TTM)
-0.40
P/E Ratio
-
Ent. Value
154.01 M
Total Shares
302.32 M
Float Shares
112.13 M
Insiders
46.34%
Institutions
27.03%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 topline data readout
rilparencel (REACT)
Stage 3b/4 chronic kidney disease (CKD) and type 2 diabetes
AcceleratedRMAT
Phase 3Cell TherapiesRenal/Genitourinary System
Unlock every PROK catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

PROK Catalyst Timeline

Dated clinical, regulatory and corporate events for ProKidney Corp.

Catalyst Timeline

Dated clinical, regulatory & corporate events for ProKidney Corp.

261Total events
10Upcoming
63Tier-1 (high impact)
2021 to 2027Coverage

Upcoming catalysts 2

T2Product Launch
Subscribe to view catalyst details
RilparencelFiled
T1Topline Readout
Subscribe to view catalyst details
RilparencelFiled

Event history 50

◆Poster PresentationRilparencelFiledPresentation
Poster on longitudinal secretome characterization of rilparencel during manufacturing (SA-PO0015) at ASN Kidney Week 2026
chronic kidney diseasesource ↗
◆Poster PresentationPresentation
Poster on GPX4-associated cytoprotective activity of autologous cell therapy in CKD models (SA-PO0013) at ASN Kidney Week 2026
chronic kidney diseasesource ↗
◆Oral PresentationRilparencelFiledPresentation
Oral presentation of rilparencel graft-adjacent remodeling data in immunocompromised rat CKD model (FR-OR044) at ASN Kidney Week 2026
chronic kidney diseasesource ↗
◆Poster PresentationRilparencelFiledPresentation
Poster of pooled Phase 2 safety and efficacy results in subset with key Phase 3 eligibility characteristics (FR-PO0498) at ASN Kidney Week 2026
chronic kidney disease with type 2 diabetessource ↗
◆Poster PresentationPresentation
Poster on human microphysiological system characterizing autologous cell therapy responses in CKD injury model (TH-PO1128) at ASN Kidney Week 2026
chronic kidney diseasesource ↗
▲Enrollment CompleteTrial
Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis
▲Enrollment CompleteTrial
Completion of full enrollment for PROACT 1
◆Management ChangeCorporate
Appointment of Kenneth Locke as Chief Technical Officer
◆Enrollment CompleteRilparencelFiledTrial
Enrollment completion for PROACT 1 accelerated approval analysis
chronic kidney disease with type 2 diabetessource ↗
◆Enrollment MilestoneRilparencelFiledTrial
Complete enrollment for accelerated approval efficacy analysis (n=~360)
chronic kidney diseasesource ↗
Unlock the full PROK catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How PROK actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-23rilparencel (REACT) Phase 2 data presentation Phase 2
Unlock 4 more PROK historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 7%
Micro Cap
(rank 48 of 671)
Percentile Rank
Showing 2 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Rilparencel Cell TherapiesNCT05099770Type 2 Diabetes MellitusPhase 3 ACTIVE NOT_RECRUITING 778Dec 1, 2029
Rilparencel Cell TherapiesCompletedNCT04115345Chronic Kidney DiseasePhase 2 COMPLETED 59Jan 31, 2023
Unlock the PROK pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every PROK program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
rilparencel
AcceleratedRMAT
advanced CKD and type 2 diabetes mellitusPhase 22026-10-22strong safety profile and kidney function stabilizationRead MoreProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026Read More
Scroll for more · summaries link to the source press release
Unlock every PROK trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock PROK insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Pereira Brian JGDirectorSell -222,948 $1.42 08/20/2026
Unlock the full PROK insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in PROK for Q2 2026.
Unlock every fund holding PROK
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in PROK
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see PROK ownership
Insider and institutional ownership, quarter by quarter.

PROK Short Interest

Shares sold short, counted twice a month.

21.91%
Short % of Float
of tradable shares sold short
24.6M
Shares Sold Short
+3.3% vs prior count
20.8 Very high
Days to Cover
trading days of normal volume to buy every short share back
1.2M
Avg Daily Volume
the average used for days to cover
Unlock PROK short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock PROK option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live PROK option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock PROK options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How PROK ranks across every disease it competes in

Competitive Position is a premium feature
See how PROK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

PROK News

PROK
Oct 22, 2026
PROKConferences/Events

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

ProKidney Corp. announced a virtual KOL event on October 27, 2026, to discuss insights into rilparencel's mechanism of action. Nephrology expert Katherine Tuttle will join company management to review findings from ASN Kidney Week 2026. The event aims to address the unmet needs in treating advanced CKD and type 2 diabetes.

Read more →
PROK
Oct 22, 2026
PROKConferences/Events

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

ProKidney Corp. announced eight abstracts for presentation at the American Society of Nephrology's Kidney Week 2026. Notably, one clinical abstract indicates a strong safety profile and kidney function stabilization in advanced CKD patients. The data supports the multifactorial mechanism of action for rilparencel, enhancing confidence in the ongoing Phase 3 PROACT 1 study.

Read more →
PROK
Aug 10, 2026
PROKPhases

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

ProKidney reported a net loss of $46.4 million for the second quarter of 2026. The company ended the period with $181.6 million in cash and marketable securities. Research and development expenses rose to $36.1 million from $25.9 million a year earlier. ProKidney also completed enrollment for the accelerated approval analysis of its Phase 3 PROACT 1 study.

Read more →
PROK
Jun 2, 2026
PROKGeneral

ProKidney Appoints Kenneth Locke as Chief Technical Officer

ProKidney Corp. has appointed Kenneth Locke as Chief Technical Officer to enhance its technical foundation as it prepares for a pivotal topline readout in Q2 2027. Locke brings extensive experience from Carisma Therapeutics and Celgene, where he led key manufacturing and regulatory functions. His leadership is expected to be vital as ProKidney advances its Phase 3 study for its autologous cell therapy targeting chronic kidney disease.

Read more →
PROK
May 15, 2026
PROKPhases

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney Corp. reported its Q1 2026 financial results, highlighting progress in its Phase 3 PROACT 1 study for rilparencel, which is expected to complete enrollment by mid-2026. The company ended the quarter with $224.9 million in cash, supporting operations into mid-2027. Positive Phase 2 results were published, and FDA alignment on the accelerated approval pathway was confirmed.

Read more →
PROK
Mar 26, 2026
PROKGeneral

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Corp. has appointed Greg Madison as Chief Commercial Officer to lead the company's commercial strategy as it advances the cell therapy rilparencel towards potential commercialization. Madison brings over two decades of experience in biopharma, having previously held leadership roles at Shield Therapeutics and Keryx Biopharmaceuticals. His expertise in nephrology will be crucial as ProKidney aims to address unmet needs in chronic kidney disease treatment.

Read more →
PROK
Mar 18, 2026
PROKPhases

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

ProKidney Corp. reported its financial results for 2025, highlighting significant progress in its Phase 3 PROACT 1 study for rilparencel, with completion of enrollment expected by mid-2026. The company has aligned with the FDA on an accelerated approval pathway, using eGFR slope as a surrogate endpoint. Financially, ProKidney ended 2025 with $270 million in cash, supporting operations into mid-2027.

Read more →
PROK
Feb 2, 2026
PROKPhases

This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney's actual results m

ProKidney is advancing its Phase 3 trial for Rilparencel, an autologous cell therapy for chronic kidney disease (CKD), aiming for potential accelerated FDA approval. The company has reported promising results from earlier trials, indicating that this treatment could stabilize kidney function. However, numerous risks hang over their operations, including potential disruptions following domestication to the U.S. and difficulties in obtaining regulatory approvals. Expectations for a Biologics License Application submission are set for 2H 2027, with several essential milestones planned for 2026.

Read more →
PROK
Jan 6, 2026
PROKConferences/Events
▲ +5.1%on this news

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

ProKidney Corp. announced that its CEO, Dr. Bruce Culleton, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company, which focuses on chronic kidney disease (CKD) treatment through cell therapy, is expected to engage in one-on-one meetings with investors during the event. ProKidney's lead product, rilparencel, is currently undergoing a Phase 3 clinical trial aimed at preserving kidney function in patients with advanced CKD and type 2 diabetes.

Read more →
PROK
Nov 10, 2025
PROKFDA Updates

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Corp. reported its third quarter 2025 financial results, highlighting promising Phase 2 data for rilparencel in chronic kidney disease (CKD) patients. The FDA has confirmed that the eGFR slope can serve as a surrogate endpoint for accelerated approval. The company has sufficient cash to support operations through mid-2027, although it continues to incur significant losses.

Read more →
PROK
Nov 6, 2025
PROKPhases

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

ProKidney Corp. presented full results from the Phase 2 REGEN-007 trial of rilparencel at ASN Kidney Week 2025. The data indicates that rilparencel may preserve kidney function in patients with advanced chronic kidney disease (CKD) and diabetes. This trial supports the ongoing Phase 3 PROACT 1 study, which aims to evaluate the efficacy of rilparencel further.

Read more →
PROK
Oct 29, 2025
PROKConferences/Events

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

ProKidney Corp. will participate in two significant healthcare conferences in November 2025. The Guggenheim Healthcare Innovation Conference will feature a fireside chat, while the Jefferies Global Healthcare Conference will include one-on-one meetings. These events aim to enhance investor engagement and showcase ProKidney's advancements in chronic kidney disease treatments.

Read more →
PROK
Oct 20, 2025
PROKConferences/Events
▲ +10.8%on this news

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025

ProKidney Corp. announced the acceptance of two abstracts for presentation at the American Society of Nephrology's Kidney Week 2025. This includes a late-breaking poster on the Phase 2 REGEN-007 study results. The event will take place from November 6-9, 2025, in Houston, TX, showcasing advancements in cellular therapy for chronic kidney disease.

Read more →
PROK
Aug 27, 2025
PROKConferences/Events

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

ProKidney Corp. will participate in the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference in September. The company's management team will engage in discussions about their innovative cellular therapies for chronic kidney disease. ProKidney's lead product, rilparencel, is currently in a Phase 3 study aimed at preserving kidney function.

Read more →
PROK
Aug 12, 2025
PROKFDA Updates

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Corp. has reported positive developments regarding their treatment rilparencel for chronic kidney disease (CKD) and diabetes. The FDA has confirmed that estimated glomerular filtration rate (eGFR) slope is an acceptable surrogate endpoint for accelerated approval, a decision made in a recent Type B meeting. In an encouraging announcement, the company revealed a 78% improvement in eGFR slope during Phase 2 REGEN-007 and has successfully enrolled more than half of the patients needed for their Phase 3 PROACT 1 study. However, the company also reported a $37 million net loss for Q2 2025, impacting their financial outlook.

Read more →
PROK
Jul 15, 2025
PROKFDA Updates
▼ -8.7%on this news

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

ProKidney Corp. has confirmed alignment with the FDA on the accelerated approval pathway for its cellular therapy, rilparencel, aimed at treating chronic kidney disease (CKD). The FDA has accepted the eGFR slope as a surrogate endpoint for a Biologics License Application (BLA). ProKidney anticipates topline data readout in Q2 2027 and has nearly completed patient enrollment for the analysis.

Read more →
PROK
Jul 9, 2025
PROKConferences/Events
▲ +16.4%on this news

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

ProKidney Corp. announced its participation in the H.C. Wainwright 4th Annual Kidney Virtual Conference. Senior management will engage in discussions about their advancements in cellular therapeutics for chronic kidney disease. The company's lead product, rilparencel, is under evaluation in Phase 2 and Phase 3 studies and has received FDA's RMAT designation.

Read more →
PROK
Jul 8, 2025
PROKPhases
▲ +515%on this news· ran to +649% by day 3shared move

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes

ProKidney Corp. announced positive topline results from the Phase 2 REGEN-007 trial of rilparencel in patients with chronic kidney disease and diabetes. The trial demonstrated a statistically significant improvement in the estimated glomerular filtration rate (eGFR) slope. The company plans to present full results at the ASN 2025 Kidney Week and has an upcoming FDA Type B meeting to discuss accelerated approval pathways.

Read more →

About ProKidney Corp.

Winston-Salem, NC 231 employees prokidney.com
Headquarters2000 FRONTIS PLAZA BLVD., WINSTON-SALEM, NC, 27103
BIOPHARMAWATCH ELITE
Trade the next PROK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime